Holen Sie sich die Stockscreener-App
0.77
5.48%
0.04
Schlusskurs vom Vortag:
$0.73
Offen:
$0.71
24-Stunden-Volumen:
142.82K
Relative Volume:
0.62
Marktkapitalisierung:
$25.72M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-10.21M
KGV:
-1.318
EPS:
-0.5842
Netto-Cashflow:
-
1W Leistung:
-0.58%
1M Leistung:
-12.49%
6M Leistung:
-34.75%
1J Leistung:
-30.00%
1-Tages-Spanne:
$0.71
$0.7838
1-Wochen-Bereich:
$0.63
$0.815
52-Wochen-Spanne:
$0.63
$2.60
Neurosense Therapeutics Ltd Stock (NRSN) Company Profile
Firmenname
Neurosense Therapeutics Ltd
Sektor
Branche
Telefon
-
Adresse
-
Compare NRSN vs VRTX, REGN, ALNY, ARGX, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NRSN
Neurosense Therapeutics Ltd
|
0.77 | 25.72M | 0 | -10.21M | 0 | -0.5842 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Neurosense Therapeutics Ltd Aktie (NRSN) Neueste Nachrichten
NeuroSense Therapeutics (NASDAQ:NRSN) Receives “Buy” Rating from D. Boral Capital - Defense World
NeuroSense Therapeutics (NRSN): Analyst Reaffirms 'Buy' Rating | - GuruFocus
If You Invested $1,000 in Neurosense Therapeutics Ltd (NRSN) - Stock Titan
NeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data Package and Near-Term Alzheimer's Readout - Finviz
NeuroSense Reschedules Health Canada Meeting as PrimeC Data Package Strengthens - TipRanks
[6-K] NeuroSense Therapeutics Ltd. Current Report (Foreign Issuer) - Stock Titan
NeuroSense delays Canada meeting to add data as Alzheimer’s results near - Stock Titan
Chart Watch: Is NeuroSense Therapeutics Ltd in a consolidation phase2026 Analyst Calls & Verified Technical Trade Signals - baoquankhu1.vn
NeuroSense Therapeutics Ltd.: Fundamental Analysis and Financial Ratings | H1Z | IL0011809592 - marketscreener.com
NeuroSense (NRSN) director Pellizzari details option and share holdings - Stock Titan
NeuroSense Therapeutics (NRSN) CMO details option and warrant holdings - Stock Titan
NeuroSense (NRSN) director details options and restricted share holdings - Stock Titan
NeuroSense (NRSN) GM Hagit Binder details share, option and RSU holdings - Stock Titan
/C O R R E C T I O N -- NeuroSense/ - PR Newswire
Bull Bear: What are NeuroSense Therapeutics Ltd Equity Warrants recent SEC filings showingStop Loss & AI Enhanced Market Trend Forecasts - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: Neurosense Therapeutics Ltd. (NRSN), Structure Therapeutics, Inc. Sponsored ADR (GPCR) and Lifecore Biomedical (LFCR) - The Globe and Mail
PrimeC New Data to Be Presented at AD/PD™ 2026 Conference - PR Newswire
Neurosense Therapeutics Ltd - Reuters
NeuroSense Therapeutics (NRSNW) Projected to Post Quarterly Earnings on Wednesday - Defense World
Director at NeuroSense (NASDAQ: NRSN) discloses equity awards and vesting - Stock Titan
EPS Watch: Whats the fair value of NeuroSense Therapeutics Ltd stock2026 Top Gainers & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
Is United Therapeutics Corporation gaining market share2026 Earnings Impact & Short-Term Swing Trade Alerts - baoquankhu1.vn
Aug Opening: Is NeuroSense Therapeutics Ltd Equity Warrant benefiting from interest rate changes2026 Momentum & Stepwise Trade Signal Guides - baoquankhu1.vn
Breakout Watch: Will NeuroSense Therapeutics Ltd Equity Warrant benefit from green energy policiesTrend Reversal & Consistent Return Investment Signals - baoquankhu1.vn
FOMO Trade: Is NeuroSense Therapeutics Ltd Equity Warrant forming a bullish divergence2026 Top Gainers & Free Safe Entry Trade Signal Reports - baoquankhu1.vn
Published on: 2026-03-17 06:01:38 - baoquankhu1.vn
NeuroSense’s ALS Drug PrimeC Shows Strong Phase 2b Results in JAMA Neurology - TipRanks
JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity - PR Newswire
Tangible book value per share of Neurosense Therapeutics Ltd. – FWB:H1Z - TradingView
Analysts Set NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Price Target at $8.50 - Defense World
Operating cash flow per share of Neurosense Therapeutics Ltd. – FWB:H1Z - TradingView
NeuroSense Shareholders Approve Increase in Registered Share Capital - The Globe and Mail
[6-K] NeuroSense Therapeutics Ltd. Current Report (Foreign Issuer) | NRSN SEC FilingForm 6-K - Stock Titan
NeuroSense "PrimeC" Market size expansion of Several Folds by 2034 - openPR.com
This Strategy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
PrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific Conference - GuruFocus
Roth/MKM initiates NeuroSense stock with buy on ALS drug potential - Investing.com Nigeria
Roth/MKM initiates NeuroSense stock with buy on ALS drug potential By Investing.com - Investing.com South Africa
Neurosense Therapeutics Ltd. Presents Long-Term Survival Data for Primec in Amyotrophic Lateral Sclerosis - marketscreener.com
Analysis Recap: Can NeuroSense Therapeutics Ltd Equity Warrant keep up with sector leadersMarket Sentiment Review & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
Long-Term Data From PARADIGM Trial Suggest Survival Benefit With PrimeC in ALS - NeurologyLive
Buy Signal: What are NeuroSense Therapeutics Ltd Equity Warrants earnings expectationsSell Signal & Real-Time Market Sentiment Reports - baoquankhu1.vn
Will NeuroSense Therapeutics Ltd. stock continue upward momentumJuly 2025 Sentiment & Fast Entry High Yield Stock Tips - Naître et grandir
Insider Sell: What are the risks of holding NeuroSense Therapeutics Ltd Equity WarrantJuly 2025 Update & Capital Efficiency Focused Ideas - baoquankhu1.vn
Revenue Check: Whats the fair value of NeuroSense Therapeutics Ltd stockRisk Management & Fast Exit and Entry Trade Guides - baoquankhu1.vn
Published on: 2026-03-06 17:33:43 - baoquankhu1.vn
NRSN SEC FilingsNeurosense Therapeutics Ltd 10-K, 10-Q, 8-K Forms - Stock Titan
Revenue Check: Is NeuroSense Therapeutics Ltd Equity Warrant forming a bullish divergence2025 Technical Patterns & Verified Momentum Stock Ideas - baoquankhu1.vn
IANS - IANS
Book value per share of Neurosense Therapeutics Ltd. – FWB:H1Z - TradingView
Buyback Watch: Is NeuroSense Therapeutics Ltd Equity Warrant stock undervalued right now2025 Market WrapUp & Verified Momentum Watchlists - baoquankhu1.vn
Finanzdaten der Neurosense Therapeutics Ltd-Aktie (NRSN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):